CIRSE Congress 2025 - The SELUTION SLR™ drug-eluting balloon (DEB) showed promising outcomes in both BTK and ATK populations.

Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, Arnsberg, DE) joins us to discuss the 12 month findings from the SUCCESS PTA study (NCT04776434). The real-world, prospective, single arm surveillance study aimed to investigate the safety and efficacy of the SELUTION SLR™ DEB compared to existing treatment options using a health economic analysis. Generic and disease specific patient reported outcome measures will be used to measure the impact of the intervention on the overall health status of patients, and the patients will be followed for five years post-procedure.

Positive outcomes were observed, with a 91.4% rate of freedom from target lesion revascularisation in the above-the-knee group, and 89.3% in the below-the-knee group.

Interview Questions:

1. What is the reasoning behind the SUCCESS PTA study?
2. Could you tell us about the health economic analysis used in this trial?
3. What was the study design and patient population?
4. What were the key findings?
5. What are the take-home messages for practice?
6. What further research is needed in this areas, and what are the next steps?

Recorded virtually from Arnsberg, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.